NeurogesX Gets FDA Approval For Pain Patch
SAN MATEO, Calif. (AP) ¿ Biotechnology company NeurogesX Inc. said Monday it received Food and Drug Administration approval for its Qutenza pain patch.
The regulatory approval is for postherpetic neuralgia, a type of nerve pain condition that results from shingles. The patch is already approved in Europe for peripheral nerve pain in non-diabetic adults.
NeurogesX plans to launch Qutenza in the United States through its own sales force in the first half of 2010.
Shares of NeurogesX rose 76 cents, or 9.2 percent, to $9 in after-hours trading after falling 4 cents to close at $8.24 during the regular trading session.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV